Newly Diagnosed Efficacy
In newly diagnosed GBM,
Optune Gio™ + TMZ provided an unprecedented long-term survival benefit
Survival with Optune Gio + TMZ vs TMZ alone was significantly higher at the 2-year landmark analysis and remained higher at 5 years1,2
Overall survival (5-year survival analysis)1-3
A standard of care proven to provide the best opportunity for greater OS at 5 years vs TMZ alone (13% vs 5%)1,4
Median OS was significantly extended with Optune Gio—by nearly 5 months (P<0.001)1,2
Optune Gio + TMZ also significantly improved PFS vs TMZ alone1,2
- Median PFS: 6.7 months vs 4.0 months (P<0.001)
More time on Optune Gio predicted increased significant survival benefit5
Median OS by monthly time (hours/day) on Optune Gio*
- Monthly usage was a predictor of survival benefit, independent of other prognostic factors such as KPS, age, or MGMT methylation status5
*Based on the amount of time Optune Gio was turned on and providing therapy over the course of a month. These data reflect the average patient usage of Optune Gio for the first 6 months of treatment (months 1-6).5
86% of patients received a survival benefit from Optune Gio because they used it more than half the time (n=388/450)5
Learn how Optune Gio increased survival for elderly patients
†Approximation, based on percentage of usage.
‡vs TMZ alone.
References: 1. Optune Gio. Instructions For Use. Novocure; 2023. 2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 3. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.1.2023. © National Comprehensive Cancer Network, Inc. All rights reserved. Accessed October 6, 2023. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. 5. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473.